🏛️ Company factsSEC filings + FINRA official data
Annual revenue $14.3B · latest quarter up 16.7% YoY · profitable (FY net income $4.5B) · short activity within its normal range.
FY revenue
$14.3B
2025-12
Latest Q YoY
+16.7%
FY net income
$4.5B
Diluted EPS
$43.07
Short volume
60.1%
20d avg 54.4% · normal
🐋 5%+ ownership filings (last 180d)
The parties below hold over 5% of this company and disclosed it to the SEC (mandatory in US markets). "Activist" filers state an intent to influence the company; "Passive" are pure investment positions.
- 2026-04-30passive (13G)VANGUARD CAPITAL MANAGEMENT LLC
- 2026-03-27passive (13G)VANGUARD GROUP INC
🎯 Market expectations
Expectation reliability Low · 41/100Nasdaq analyst consensus · the pre-news baseline
There is no clear consensus on this stock (thin coverage or wide disagreement) — 'beating expectations' means little here.
- Jun 2026$12.53 vs $8.00+56.62%
- Mar 2026$7.50 vs $6.28+19.43%
- Dec 2025$9.30 vs $8.28+12.32%
- Sep 2025$9.63 vs $7.52+28.06%
Analyst estimates, not our forecast · not investment advice
What's moving this stock lately
0 direct · 1 2nd-order · 0 thematicRanked by impact strength · strength = estimated move × freshness decay (shorter-lived effects decay faster)
- #1▼0.59%2nd-orderAMGEN'S REPATHA® REDUCES RISK OF DEATH IN PATIENTS AT HIGH RISK FOR A FIRST HEART ATTACK OR STROKE9d ago
Praluent, its PCSK9 rival co-marketed with Sanofi, faces intensified competition as Repatha's label expands
Also named: AMGN · NVS · ESPR
🕰️ Price × news · engine report card
Drag to pan, scroll to zoom · real daily bars and volume
📜 Call history (newest first
10 engine calls on this stock — each with direction, magnitude and its verified outcome · sign up to view
Sign up · free 7-day trial →Impact chains · crowding · conviction engine · insider signals — free 7-day trial on signup.
Sign up · free 7-day trial →